中科院武汉病毒研究所发现尼帕病毒潜在治疗药物

Core Insights - The research team from Wuhan Institute of Virology has discovered that the oral nucleoside drug VV116 exhibits high antiviral activity against the Nipah virus, providing new hope for the treatment of this highly lethal emerging infectious disease [2][3] Group 1: Research Findings - VV116, a novel oral nucleoside antiviral drug, has been approved for the treatment of COVID-19 in Uzbekistan and China [2] - The study demonstrated that VV116 and its active metabolites significantly inhibit the Nipah virus in vitro, including both Malaysian strain NiV-M and Bangladeshi strain NiV-B [2] - In a lethal dose infection model using golden hamsters, VV116 administered at a dose of 400 mg/kg increased the survival rate of the animals to 66.7% and significantly reduced viral loads in the lungs, spleen, and brain [2] Group 2: Public Health Implications - The Nipah virus has a mortality rate ranging from 40% to 70% and has been a growing public health concern since its first outbreak in Malaysia in 1998 [1] - The World Health Organization (WHO) has classified the Nipah virus as a high-priority regional threat due to its wide host range and high fatality rate, with no approved drugs or vaccines currently available [1] - The findings from this research provide a potential preventive treatment option for healthcare workers and laboratory personnel at high risk of exposure to the Nipah virus [3]